Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ocugen, Inc. - Common Stock
(NQ:
OCGN
)
1.230
+0.050 (+4.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocugen, Inc. - Common Stock
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
36
37
Next >
Where Will Ocugen Be in 3 Years?
↗
November 08, 2021
Most likely in the doldrums, but it could be temporary.
Via
The Motley Fool
Ocugen Stock Looks Poised to Take a Tumble Right Here
↗
November 08, 2021
After WHO granted Covaxin a limited Emergency Use Listing, many institutions and hedge funds are likely to sell or short OCGN stock.
Via
InvestorPlace
Is Ocugen a Buy?
↗
November 07, 2021
It'll take more than regulatory approvals of its vaccine for it to become a good investment.
Via
The Motley Fool
Ocugen Seeks FDA Emergency Use Nod For Covaxin COVID-19 Vaccine In Kids
↗
November 05, 2021
Ocugen Inc (NASDAQ: OCGN) said that it sent a request to the FDA for an emergency authorization for its COVID-19 vaccine candidate BBV152, known as Covaxin outside...
Via
Benzinga
With Ocugen Stock: Follow The Lead of Traders and ‘Sell The News’
↗
November 05, 2021
WHO approval for Covaxin doesn't change the game much for OCGN stock, steer clear as it slides back to lower prices.
Via
InvestorPlace
Here's Why Shares of Moderna, Novavax, and Ocugen Have All Been Extremely Volatile This Week
↗
November 05, 2021
Multiple earnings reports and regulatory updates shook up the coronavirus vaccine space this week.
Via
The Motley Fool
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
↗
November 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...
Via
Benzinga
This Surprising FDA Announcement Could Be Huge for Ocugen
↗
November 05, 2021
The agency will allow vaccine boosters to be mixed and matched.
Via
The Motley Fool
Is Ocugen's Surge Much Ado About Nothing?
↗
November 05, 2021
The short answer: Yes.
Via
The Motley Fool
81 Biggest Movers From Yesterday
↗
November 05, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8...
Via
Benzinga
Avoid Ocugen — The Vaccine Is Too Little, Too Late
↗
November 04, 2021
With high percentage of vaccination in U.S. and Canada, Ocugen has a limited addressable market. Limited cash flow visibility from vaccine. With the company still waiting for official FDA approval for...
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
November 04, 2021
Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
November 04, 2021
Gainers Evaxion Biotech (NASDAQ:EVAX) shares increased by 244.61% to $22.4 during Thursday's pre-market session. The company's market cap stands at $430.0 million...
Via
Benzinga
4 Stocks Insiders Are Selling
↗
November 04, 2021
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to...
Via
Benzinga
55 Stocks Moving In Thursday's Mid-Day Session
↗
November 04, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the...
Via
Benzinga
24 Stocks Moving in Thursday's Pre-Market Session
↗
November 04, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) rose 143.5% to $15.83 in pre-market trading after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) rose 72.6% to $4.09...
Via
Benzinga
86 Biggest Movers From Yesterday
↗
November 04, 2021
Gainers FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire Fazoli’s Restaurant Chain for $130 million....
Via
Benzinga
Ocugen Neared $16 Yesterday, But I’ll Eat 4 Hats If It Gets to $32
↗
November 03, 2021
OCGN stock has moved higher despite little evidence anything’s changed regarding Ocugen’s revenue potential in the U.S.
Via
InvestorPlace
Most Active Equity Options For Midday - Wednesday, Nov. 3
↗
November 03, 2021
Top Tickers: TSLA, AMC, AMD, AAPL, F, BBBY, LCID, GME, BB, NVDA, Z, UBER, PLTR, HOOD, OCGN, AAL, ATVI, SOFI, PFE, FB.
Via
Talk Markets
Why Ocugen Stock Is Falling Today
↗
November 03, 2021
The biotech received some good news for its most important product. So why is the stock down?
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
November 03, 2021
Gainers iRhythm Technologies (NASDAQ:IRTC) stock moved upwards by 52.78% to $117.34 during Wednesday's regular session. iRhythm Technologies's stock is trading at...
Via
Benzinga
BZ Chart Of The Day: Will Ocugen Remember?
↗
November 03, 2021
They say that markets have memories. It’s true, and holders and traders of Ocugen, Inc. (NASDAQ:
Via
Benzinga
Ocugen's India Partnered COVID-19 Vaccine Gets WHO Approval: Report
↗
November 03, 2021
WHO's Technical Advisory Group has recommended the Emergency Use Listing status for Bharat Biotech's COVID-19, Covaxin. Read Next: Ocugen Reverses Course From Monday...
Via
Benzinga
Here's Why Ocugen Stock Skyrocketed 64.9% in October
↗
November 03, 2021
The biotech stock is now up a staggering 756% year to date.
Via
The Motley Fool
OCGN Stock Alert: WHO Issues Emergency-Use Listing for Covaxin
↗
November 03, 2021
The WHO has finally given Covaxin emergency approval, putting OCGN stock in the spotlight. Will Ocugen be able to bring doses to the U.S.?
Via
InvestorPlace
3 Explosive Biotech Stocks -- Could They Shoot Even Higher?
↗
November 03, 2021
These biotech stocks have recently been responsible for a slew of rocketship emojis.
Via
The Motley Fool
PFE Stock Alert: 3 Catalysts Giving Pfizer Stock a Shot in the Arm Today
↗
November 02, 2021
Pfizer is getting ready to start shipping children's vaccines, and PFE stock is rising. That's not the only good news for investors, though.
Via
InvestorPlace
OCGN Stock Alert: Why Ocugen Shares Are Drawing Eyes Ahead of Nov. 3
↗
November 02, 2021
A key WHO ruling that could materialize as soon as tomorrow has investors considering where OCGN stock could be headed this week.
Via
InvestorPlace
Check Out What Whales Are Doing With OCGN
↗
November 02, 2021
Someone with a lot of money to spend (and possibly insider knowledge) has taken a bearish stance on Ocugen (NASDAQ:OCGN). And retail traders should know. We noticed this today...
Via
Benzinga
An Approval by WHO Would Not Help Ocugen
↗
November 02, 2021
Ocugen is forging ahead with its plans for regulatory approval, but that doesn't make OCGN stock any more worthy of your capital.
Via
InvestorPlace
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
36
37
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.